AIM Vaccine Co., Ltd. has announced the submission of its independently developed 13-valent pneumonia conjugate vaccine to the National Medical Products Administration (NMPA) in China for drug marketing registration. This follows the successful completion of Phase III clinical trials, which demonstrated favorable immunogenicity and safety profiles, meeting all pre-defined clinical objectives.
The vaccine is intended for use in infants and children aged 6 weeks to 5 years, providing protection against invasive diseases caused by 13 different pneumonia serotypes. These diseases include bacteremia pneumonia, meningitis, septicemia, and bacteremia, all of which pose significant health risks to young children.
Clinical Trial Outcomes
The Phase III clinical trials, now unblinded, have provided robust data supporting the vaccine's efficacy and safety. According to AIM Vaccine, the results indicate a strong immune response and a safety profile consistent with expectations for this type of vaccine. Specific data regarding the magnitude of the immune response (e.g., geometric mean titers, seroconversion rates) and the incidence of adverse events were not detailed in the announcement but will likely be part of the NMPA's review process.
Market Opportunity
Pneumococcal disease is recognized by the World Health Organization (WHO) as a high-priority target for vaccine prevention. Pfizer's 2023 annual report indicated approximately USD 6.44 billion in global sales for its pneumonia conjugate vaccine. However, the penetration rate of the 13-valent pneumonia conjugate vaccine in the approved age group in China is an estimated 25.9%, significantly lower than the over 80% penetration rate in the United States, suggesting substantial growth potential.
In 2022, domestic sales of the product in China reached approximately RMB 9.5 billion. China Insights Industry Consultancy Limited forecasts the market size to reach RMB 35 billion by 2030. Before the COVID-19 pandemic, the 13-valent pneumonia conjugate vaccine was the world's top-selling vaccine for ten consecutive years. Authoritative organizations estimate the global underserved demand for these vaccines to be as high as 180 million doses.
Manufacturing and Supply
AIM Persistence Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of AIM Vaccine, has secured the necessary drug production license for manufacturing the vaccine. Currently, only three companies are approved to supply this vaccine globally. AIM Vaccine anticipates becoming a significant market supplier upon product launch, which is expected to substantially improve the company's financial performance.
